X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Buyouts Dwindle As Pharma Sector Faces Pricing Concerns

    Unconstitutional Price-Setting Provisions: PhRMA Asserts

    Pharma May Lose Out To Competition Due To EU Health Package

    Pharma Trade Group Sues Biden Admin Over Medicare Drug Costs

    Chronic Pain Gene Discovered By The University Of Oxford

    Cell & Gene Therapy CDMO Market – Steady Growth On The Cards

    Cell And Gene Therapy CDMO Services Set For Rapid Growth

    Growth Forecast For Asia Pacific Pharmaceutical CDMO Market

    Small Molecule Innovator CDMO Market Set For Heavy Growth

    Scientists Say COVID-19 May Have A New Therapeutic Option

    Pharma Sterility Testing Market Set For Remarkable Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Buyouts Dwindle As Pharma Sector Faces Pricing Concerns

    Unconstitutional Price-Setting Provisions: PhRMA Asserts

    Pharma May Lose Out To Competition Due To EU Health Package

    Pharma Trade Group Sues Biden Admin Over Medicare Drug Costs

    Chronic Pain Gene Discovered By The University Of Oxford

    Cell & Gene Therapy CDMO Market – Steady Growth On The Cards

    Cell And Gene Therapy CDMO Services Set For Rapid Growth

    Growth Forecast For Asia Pacific Pharmaceutical CDMO Market

    Small Molecule Innovator CDMO Market Set For Heavy Growth

    Scientists Say COVID-19 May Have A New Therapeutic Option

    Pharma Sterility Testing Market Set For Remarkable Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

Unconstitutional Price-Setting Provisions: PhRMA Asserts

Content Team by Content Team
28th June 2023
in FDA Approvals, News

NICA, PhRMA, and GCCA lodged a complaint in the U.S. District Court for the Western District of Texas, asserting that the price setting provisions outlined in the Inflation Reduction Act infringe upon the Constitution. They argue that these provisions lack checks and balances, deny administrative and judicial review, and impose an excessive fine, all of which should render them unconstitutional.

NICA CEO Brian Nyquist stated that while they support lower costs for patients, infusion providers lack control over medication prices. He highlighted the potential negative consequences of the government’s price-setting provisions in the IRA, including reduced reimbursement below acquisition cost and decreased community-based infusion capacity. Nyquist mentioned an analysis projecting a significant drop in income for office-based infusion centers and emphasized the need for litigation to protect NICA members and preserve access to these centers.

GCCA Executive Director Andrew Spiegel expressed concern about the rising rate of colorectal cancer among Americans under 55. He emphasized the need for more effective treatments and criticized the price-setting provisions in the IRA for impeding progress and disregarding patient input. Spiegel stated that GCCA joined the lawsuit to advocate for better support and outcomes for colorectal cancer patients.

PhRMA President and CEO Stephen J. Ubl criticized the price-setting scheme in the Inflation Reduction Act, stating that it threatens research, and patients’ access to medicines, and violates the U.S. Constitution. He expressed hope that the court would recognize these concerns and declare the provisions unconstitutional.

The price-setting provisions outlined in the Inflation Reduction Act are subject to various constitutional violations, warranting a declaration of unconstitutionality. These violations are as follows:

  • The price-setting provisions in the Inflation Reduction Act violate the separation of powers by granting excessive authority to HHS without proper constraints, in violation of constitutional nondelegation principles.
  • The price-setting scheme denies manufacturers the right to provide input and seek review, infringing upon their Fifth Amendment due process rights. HHS’s proposed guidelines further undermine transparency in the process.
  • The excise tax imposed by the Act as a means of enforcing compliance constitutes an excessive fine, violating the Eighth Amendment’s Excessive Fines Clause.

The complaint seeks relief in the form of declaring the price-setting scheme unconstitutional based on the violations of nondelegation and separation-of-powers principles. Additionally, it aims to declare the excise tax unconstitutional, citing its inconsistency with the Eighth Amendment. The complaint also requests the recognition of the violation of due process rights and the implementation of adequate procedural processes, including public notice, comment, and judicial review. Furthermore, it seeks to enjoin HHS from implementing the price-setting scheme without these safeguards and to prevent the government from enforcing the excise tax specified in the Act.

Previous Post

Pharma May Lose Out To Competition Due To EU Health Package

Next Post

Buyouts Dwindle As Pharma Sector Faces Pricing Concerns

Related Posts

FDA Approvals

Buyouts Dwindle As Pharma Sector Faces Pricing Concerns

28th June 2023
Drug Development

Pharma May Lose Out To Competition Due To EU Health Package

28th June 2023
FDA Approvals

Pharma Trade Group Sues Biden Admin Over Medicare Drug Costs

28th June 2023
Adapting Digital Transformation In The Life Sciences Sector
IPR Data Management

Adapting Digital Transformation In The Life Sciences Sector

21st June 2023
Drug Development

Cell And Gene Therapy CDMO Services Set For Rapid Growth

17th June 2023
Drug Development

Growth Forecast For Asia Pacific Pharmaceutical CDMO Market

17th June 2023
Next Post

Buyouts Dwindle As Pharma Sector Faces Pricing Concerns

Latest News

FDA Approvals

Buyouts Dwindle As Pharma Sector Faces Pricing Concerns

28th June 2023
FDA Approvals

Unconstitutional Price-Setting Provisions: PhRMA Asserts

28th June 2023
Drug Development

Pharma May Lose Out To Competition Due To EU Health Package

28th June 2023
FDA Approvals

Pharma Trade Group Sues Biden Admin Over Medicare Drug Costs

28th June 2023
Adapting Digital Transformation In The Life Sciences Sector
IPR Data Management

Adapting Digital Transformation In The Life Sciences Sector

21st June 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In